Genomeditech (Shanghai) Co.,Ltd.
Order: 021-68455258/50432826/50432825
Toll-free: 400 627 9288
Email: service@genomeditech.com

Anti-PD1 mIgG2b Antibody(Pembrolizumab)

Product information

GM-88203AB-10	10 μg
GM-88203AB-100	100 μg
GM-88203AB-1000	1 mg

Antibody Information

Species Reactivity	Human;
Clone	Pembrolizumab
Source/Isotype	Mouse IgG2b, Kappa
Application	/
Specificity	Detects PD1
Gene	PD1
Other Names	PDCD1, PD1, CD279, SLEB2
Gene ID	6622 (human)
Background	Pembrolizumab is an anti-PD-1 monoclonal antibody developed by Merck & Co. , Ltd. . Its research background can be traced back to the proposal and verification of the immune checkpoint theory. Early studies showed that Pembrolizumab demonstrated an objective response rate of 40% and a progression-free survival of more than 2 years in patients with melanoma, data that supported its becoming the first globally approved anti-PD-1 drug in 2014, the initial indication was unresectable or metastatic melanoma. With the deep understanding of the PD-1/PD-L1 pathway mechanism, the indications of Pembrolizumab have rapidly expanded to more than a dozen solid tumors, such as non-small-cell lung carcinoma, head and neck squamous cell carcinoma, triple-negative breast cancer, etc. , and achieve precision therapy through biomarker screening. Its clinical value is not only reflected in the single-agent efficacy, but also in the combination with chemotherapy, targeted drugs or immune cell therapy, which significantly prolongs the survival of patients. As a benchmark drug in the field of immune checkpoint inhibitors, the development and clinical application of Pembrolizumab have promoted the paradigm shift of cancer treatment from traditional chemotherapy to immunotherapy, it also provides an important reference for the follow-up bispecific monoclonal antibody, ADC drugs and other innovative therapies.
Storage	Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.

Version:3.1

Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

SDS-PAGE



On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is more than 95% verified by SEC-HPLC.

Version:3.1